Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) EBT Margin (2020 - 2025)

Historic EBT Margin for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q1 2025 value amounting to 7405.81%.

  • Rani Therapeutics Holdings' EBT Margin changed N/A to 7405.81% in Q1 2025 from the same period last year, while for Sep 2025 it was 3966.5%, marking a year-over-year decrease of 82039200.0%. This contributed to the annual value of 5504.28% for FY2024, which is N/A changed from last year.
  • Rani Therapeutics Holdings' EBT Margin amounted to 7405.81% in Q1 2025.
  • Rani Therapeutics Holdings' 5-year EBT Margin high stood at 1474.25% for Q2 2023, and its period low was 7405.81% during Q1 2025.
  • Over the past 4 years, Rani Therapeutics Holdings' median EBT Margin value was 402.42% (recorded in 2021), while the average stood at 575.42%.
  • In the last 5 years, Rani Therapeutics Holdings' EBT Margin skyrocketed by 42336800bps in 2021 and then plummeted by -26138700bps in 2024.
  • Over the past 4 years, Rani Therapeutics Holdings' EBT Margin (Quarter) stood at 279.65% in 2021, then soared by 488bps to 1084.49% in 2023, then plummeted by -241bps to 1529.38% in 2024, then plummeted by -384bps to 7405.81% in 2025.
  • Its EBT Margin stands at 7405.81% for Q1 2025, versus 1529.38% for Q4 2024 and 1084.49% for Q4 2023.